NCT00440362 - A Phase 1/2 Clinical Trial of an Alphavirus Replicon Vaccine for Influenza | Biotech Hunter

Enrollment

216

Participants

Timeline

Start Date

April 30, 2007

Primary Completion Date

September 30, 2007

Study Completion Date

September 30, 2007

Conditions

Influenza

Interventions

BIOLOGICAL

AVX502

1 dose at 2e8 IU given at t=0 via IM route

BIOLOGICAL

AVX502

1 dose at 2e7 IU given at T=0 via the IM route

BIOLOGICAL

AVX502

1 dose at 2e7 IU given at t=0 via the SC route

BIOLOGICAL

AVX502

1 dose at 2e8 IU given at T=0 via the SC route

BIOLOGICAL

AVX502

2 doses at 2e7 IU given at T=0 and 8 weeks via the IM route

BIOLOGICAL

AVX502

2 doses at 2e8 IU given at T=0 and 8 weeks via the IM route

BIOLOGICAL

AVX502

2 doses of 2e7 IU given at t=0 and 8 weeks via the SC route

BIOLOGICAL

AVX502

2 doses at 2e8 IU given at T=0 and 8 weeks via the SC route

BIOLOGICAL

Placebo

1 dose of placebo given at T=0 via the IM route

BIOLOGICAL

Placebo

1 dose of placebo given at T=0 via the SC route

BIOLOGICAL

Placebo

2 doses of placebo given at T=0 and 8 weeks via the IM route

BIOLOGICAL

Placebo

2 doses of placebo given at T=0 and 8 weeks via the SC route

Trial Locations (1)

66219

Johnson County Clin-Trials, Lenexa